Scientists discover experimental therapy for chronic inflammatory bowel disease, colon cancer

July 29, 2015, University of California, Los Angeles

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information.

High levels of microRNA-214 are typically seen in UC patients, who have an increased risk of developing colon cancer. It is still unclear why colitis patients also develop colon cancer.

Thirty percent of all patients who complain of gastrointestinal pain are typically diagnosed with "indeterminate " by their gastroenterologist. Even if the patient has all available biomarkers and underwent a colonoscopy, many clinicians are still unable to determine if the patient has UC or Crohn's disease.

In the two-year study, UCLA Jonsson Comprehensive Cancer Center member Dr. Dimitrios Iliopoulos and his colleague Dr. Christos Polytarchou, UCLA assistant professor of digestive diseases, examined 401 colon tissue samples from patients in the United States and Europe with UC, Crohn's disease, irritable bowel syndrome, sporadic and colitis-associated colon cancer, and compared them to specimens from people without these disorders or diseases.

The team hoped the research would assist physicians in diagnosing this disease correctly and provide the appropriate treatment, said Dr. Iliopoulos. They developed a systems approach that could expedite the drug discovery process by utilizing sophisticated computer programs and high-tech robotics that combines molecular and clinical information to identify the most important genes to create new drugs. The integration of this complex data is what led them to discover a new microRNA-214 chemical inhibitor to treat UC and colon cancer.

"The first steps of the drug discovery process usually take five to six years and by using our novel approach we expedited the process only in two years," said Iliopoulos, an associate professor of digestive diseases.

Previous studies have mentioned findings related to inflammatory responses in both sporadic and colitis-associated colon cancers, but it was unclear until now whether the inflammatory signals regulated the same signaling pathways.

"We evaluated this drug in mice with and and found that in both cases it was highly effective to suppress these diseases," Iliopoulos said.

Colorectal cancer, or colon cancer, is the third leading cause of cancer-related deaths in the United States (when men and women are considered separately), and the second leading cause when both sexes are combined. The American Cancer Society estimates 93,090 new cases of and 39,610 new cases of will be diagnosed in the United States in 2015. Additionally, 49,700 people are expected to die from the disease this year.

Iliopoulos will continue testing the microRNA-214 inhibitor and will apply for an investigational new drug application with the U.S. Food & Drug Administration. He hopes to eventually begin phase I clinical trials for patients with UC next year.

The study is now available online, and the print edition will be released Oct. 1, 2015 in Gastroenterology.

Explore further: Elective surgery is associated with lower risk of death than drugs for ulcerative colitis

More information: "MicroRNA214 is Associated with Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-associated Cancer in Mice," Gastroenterology, Available online 6 June 2015, ISSN 0016-5085,

Related Stories

Elective surgery is associated with lower risk of death than drugs for ulcerative colitis

July 13, 2015
Patients over 50 with ulcerative colitis (UC), a chronic disease of the colon, who undergo surgery to treat their condition live longer than those who are treated with medications, according to a new study from the Perelman ...

Researchers identify new stem cell population important in the growth of colon cancer

June 16, 2015
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly ...

Study identifies genetic factors involved in pediatric ulcerative colitis

September 3, 2014
UCLA researchers were part of a team that has discovered the interplay of several genetic factors that may be involved in the development of early-onset ulcerative colitis, a severe type of inflammatory bowel disease.

Two studies identify potential new drug for Crohn's disease and ulcerative colitis

August 21, 2013
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. ...

Potential new treatment for gastrointestinal cancers discovered

January 17, 2013
(Medical Xpress)—Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential ...

High-value research of 2014 presented for gastroenterology

May 6, 2015
(HealthDay)—Articles relating to esophageal diseases, pancreatic cancer, colorectal cancer, inflammatory bowel disease, liver disease, and other topics are included in a special gastroenterology and hepatology update summary ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.